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Abstract
Background: The liver-derived C-reactive protein (CRP) is a sensitive and systemic biomarker of inflammation, and
has been associated with increased risk of developing type 2 diabetes in populations other than Chinese. Therefore,
we prospectively examined the relation between plasma levels of CRP and risk of type 2 diabetes (T2D) among a
Chinese population.
Methods: Plasma high-sensitive CRP (hs-CRP) concentrations were assayed among 571 T2D cases and 571 controls
nested in the prospective cohort of the Singapore Chinese Health Study. Both cases and controls were free
of physician-diagnosed diabetes, cardiovascular disease and cancer at blood collections (1999–2004). Incident
physician-diagnosed T2D cases were self-reported during the follow-up visits (2006–2010), and controls were
matched for age (±3 years) and date (±6 months) of blood collection and gender. Multivariable logistic regression
models were used to compute the odds ratio (OR) and the corresponding 95% confidence intervals (CIs).
Results: The mean (SD) concentrations of hs-CRP were 2.79 (2.65) and 1.86 (2.03) mg/L, respectively, in cases
and controls (P < 0.001). After multivariate adjustment for T2D risk factors such as lifestyle, body mass index,
plasma triglycerides and HDL cholesterol, the OR comparing the extreme quartiles of hs-CRP was 1.74 [95% CI
1.12–2.70; P for trend = 0.016]. When the analysis was limited to 279 cases who had HbA1c ≥6.5% at the time
of blood collection and their controls, the OR comparing the extreme quartiles of hs-CRP was 2.43 (95% CI 1.
25–4.71; P for trend = 0.003). When confined to the other 292 subjects with HbA1c <6.5% and their controls,
the corresponding OR was 1.24 (95% CI 0.64–2.39; P for trend = 0.93).
Conclusions: We found that CRP was not associated with increased risk of incident diabetes in this cohort of
Chinese in Singapore. Previous positive findings from prospective studies might be partly due to undiagnosed
T2D among the cases during blood collection.
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Background
C-reactive protein (CRP) is synthesized by the liver and
has been shown to be a sensitive and systemic biomarker
of inflammation [1]. A number of prospective cohort
studies and nested case–control studies have reported
that CRP is associated with increased risk of developing
type 2 diabetes (T2D) [2]. A recent meta-analysis of 18
prospective studies found that the overall relative risk
(RR) of T2D was 1.26 (95% confidence interval [CI]
1.16–1.37) per 1 log mg/L increment in CRP levels [2].
However, most of the studies have been conducted in
US or European populations [2], and two studies were
done in Japanese adults [3, 4]. To the best of our
knowledge, no study has specifically investigated the
relation between CRP and risk of incident T2D in a
Chinese population.
A few cross-sectional studies have been conducted in
Chinese population, and suggest that CRP is positively
related to prediabetes (including hyperglycemia and
metabolic syndrome) and prevalent diabetes [5–11].
However, the temporal relations cannot be determined
in cross-sectional studies and reverse causality is a major
concern. The positive relation in cross-sectional studies
or case–control studies could be due to CRP being a
consequence of hyperglycemia. Therefore, a prospective
study is needed to ascertain the elevation of CRP before
the onset of hyperglycaemia in the development of T2D.
Ye et al. [12] recently included elevated CRP levels in a
prediction model of incident T2D in a 6-year follow-up
study of 1912 Chinese adults aged 50–70 years, but the
exact association between CRP and diabetes risk was not
reported. Studies have consistently shown that circulat-
ing CRP levels are generally lower among Asians than
Caucasians and Hispanic populations [5, 13, 14]. There-
fore, it is of scientific interest whether CRP could predict
the onset of diabetes in Chinese population with rela-
tively lower levels. In this prospective, nested, case–con-
trol study, we examined the role of CRP in predicting
the development of incident T2D independent of obes-
ity, lifestyle and blood lipid profiles in Chinese adults.
Methods
Study population
The design of the Singapore Chinese Health Study
(SCHS) has been described previously [15]. Briefly, the
SCHS was established between 1993 and 1998 when
63,257 Chinese adults aged 45–74 years residing in
Singapore responded to an in-person interview including
questions on usual diet, demographics, height and
weight, smoking and drinking habits, usual physical ac-
tivity, and medical history including physician diagnosed
diabetes, hypertension, coronary heart disease, stroke
and cancer. A total of 52,322 participants were success-
fully re-contacted via telephone between 1999 and 2004
(follow-up I) to update certain lifestyle practices (e.g.,
smoking habits and alcohol consumption), body weight
and medical history (e.g., diabetes, hypertension, coron-
ary heart disease, and stroke). They were also invited to
donate their blood samples and 32,535 participants
agreed and gave their morning blood samples. The
current study used the date of blood sample collection at
follow-up I visits as the baseline. Participants (n = 39,528)
were re-contacted again in 2006–2010 (follow-up II) to
update their lifestyle habits and medical history, and
among them, 25,477 donated blood samples at follow-up
I. The study has been approved by the Institutional Review
Boards at the National University of Singapore and Uni-
versity of Pittsburgh, and informed consent was provided
with completion of the baseline interview.
Ascertainment of diabetes
History of physician-diagnosed diabetes was asked in
baseline questionnaires administered by a trained
interviewer. The diabetes status was inquired again by
the following question asked during the first and sec-
ond follow-up telephone interviews: “Have you been
told by a doctor that you have diabetes (high blood
sugar)?” If the answer was “yes”, participants were
also asked for the age at which they were first diag-
nosed. The prevalent diabetes cases were those who
reported to have diabetes at baseline or follow-up I
visits, and the incident diabetes were those who re-
ported to have diabetes only at follow-up II visits and
after the donation of blood specimens. The robust-
ness and accuracy of the self-reported diabetes cases
was validated in another study analyzing 1651 cohort
participants using two complementary methods [16]:
949 diabetes cases were validated by a hospital-based
discharge summary database and 702 cases via a supple-
mentary questionnaire regarding symptoms, diagnostic
tests and diabetes treatment during the telephone inter-
view. A positive predictive value of 99% was found in the
validation study, suggesting that the self-reported history
of diabetes was a reliable measure of diabetes status of the
study population.
Assessment of confounders
Potential confounders were evaluated at baseline and
follow-up I visits. The body mass index (BMI) was calcu-
lated as self-reported body weight in kilograms divided
by the square of height in meters. The self-reported BMI
has been found to be linearly associated with risk of dia-
betes in this cohort [17]. Smoking status was coded as
never, former and current smoking, and alcohol con-
sumption was coded as never/occasional, weekly and
daily drinking based on the follow-up I questionnaires.
Education level (no, primary school, secondary school
and above) and moderate physical activity levels (<0.5,
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0.5–3.9, and ≥4.0 hours/week) were obtained from base-
line questionnaires.
Selection of cases and controls
For the current analysis, we established a nested case–
control study of 571 cases and 571 matched controls
within SCHS. All cases and controls were free of
physician-diagnosed diabetes, cardiovascular disease and
cancer at baseline interview as well as at blood collection
(1999–2004). Incident self-reported T2D cases were
identified during the follow-up II visits during 2006–
2010, and controls who were free of diabetes and cardio-
vascular disease were matched, at the 1:1 ratio, with the
cases on age (±3 years) and date (±6 months) of blood
collection, sex and dialect group. In addition, all selected
controls were tested for hemoglobin A1c (HbA1c) to
identify undiagnosed T2D. All subjects HbA1c ≥6.0%
were ineligible for the study and a replacement control
with the same matching criteria was randomly chosen
among the remaining eligible subjects. The study flow is
shown in Additional file 1: Figure S1.
Laboratory procedures
A 20-mL peripheral blood sample was obtained from
each consenting subject. Immediately after blood collec-
tion, the tubes were put on ice during transport from
the subjects’ homes to the laboratory. All of the speci-
mens were then separated into various components
(plasma, serum, red blood cells, and buffy coat). All of
the specimens were subsequently stored in −80 °C
freezers for long-term storage. Frozen plasma aliquots
from case and control subjects were selected for simul-
taneous analysis at the same batch at the National Uni-
versity Hospital Reference Laboratory. Plasma hs-CRP
levels were measured via colorimetric method on a
chemistry analyzer (AU5800 Analyzer, Beckman Coulter,
Brea, CA). The within-assay and between-assay coeffi-
cients of variation (CV) were 0.5–1.4% and 1.0–1.6%, re-
spectively. Blood lipids [total cholesterol, triglycerides
(TG) and HDL cholesterol (HDL-C)] were also mea-
sured via colorimetric method on the AU 5800 system,
and the within-assay and between-assay CVs were all
less than 1.3%. Hemoglobin A1c (HbA1c) was measured
by HPLC method using Bio-Rad Variant II™ System
(Bio-Rad Laboratories, Hercules, CA) in red blood cells.
Statistical analysis
Study participants were divided into quartiles according
to the distribution of hs-CRP levels among control sub-
jects, and the lowest quartile served as the reference
group. We used conditional logistic regression to model
the CRP-T2D association with adjustment for age (con-
tinuous), BMI (continuous), smoking status, physical ac-
tivity, alcohol use, history of hypertension, plasma TG
and HDL-C levels. Tests of linear trend across increas-
ing quartiles were conducted using the median value of
each quartile and treating it as a continuous variable.
We also calculated the risk of T2D associated with per 1
log mg/L increment in hs-CRP levels, in order to com-
pare our results with previous ones [2]. Some previous
studies have suggested potential sex differences in the
association [18], thus, we tested the interaction by in-
cluding the interaction term of log hs-CRP levels (con-
tinuous) and sex in the model, and then conducted a
stratified analysis by sex using sex-specific quartiles.
Similar stratified analysis was also done by baseline BMI
status (<23 and ≥23 kg/m2), and in this stratified ana-
lysis, unconditional logistic regression models were used
with further adjustment for sex and dialect. All P values
were two-sided. Data were analyzed with STATA version
14 (Stata Corp, College Station, Texas).
Results
Among T2D cases, the mean (±SD) age at diagnosis was
63.2 ± 6.4 years and the mean (±SD) duration between
blood donation and diagnosis of T2D was 4.0 ± 1.7 years.
Characteristics of study participants assessed at blood
collections (1999–2004) are shown in Table 1. The mean
age of the participants was 59.7 (SD 6.2) years, and
41.3% were males. As expected, diabetic participants had
high-risk profiles except for the matching factors. They
were heavier, were more likely to have history of hyper-
tension than control subjects. No significant differences
were found for education level, smoking status, alcohol
drinking and physical activity levels. Regarding the
plasma biomarkers, diabetic cases had higher levels of
HbA1c, random glucose and insulin, and triglycerides,
but lower HDL-cholesterol levels. The mean (SD) con-
centration of hs-CRP was 2.79 (2.65) and 1.86 (2.03)
mg/L, respectively, in cases and controls (P < 0.001).
Among the healthy control participants, hs-CRP was in-
versely correlated with levels of HDL-C (Pearson’s coeffi-
cient r = −0.15), and positively correlated with TG levels
and BMI (Pearson’s coefficient r = 0.11 and 0.26, respect-
ively) (data not shown).
After multivariate adjustment for demographic and
lifestyle factors, the odds ratio (OR) comparing the ex-
treme quartiles of hs-CRP was 2.70 (95% CI 1.85–3.95; P
for trend <0.001; Table 2). Further adjustment for BMI,
plasma levels of TG and HDL-C attenuated the association
but it remained significant (OR = 1.74 comparing the ex-
treme quartiles of hs-CRP; 95% CI 1.12–2.70; P for trend =
0.016). Among the cases, 279 subjects had HbA1c ≥6.5% at
the time of blood collection and the OR comparing the
extreme quartiles of hs-CRP was 2.43 (95% CI 1.25–4.71;
P for trend = 0.003). The other 292 subjects had HbA1c
<6.5% at blood collection and the corresponding OR was
1.24 (95% CI 0.64–2.39; P for trend = 0.93).
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The OR (95% CI) for T2D of each 1 log mg/L incre-
ment in hs-CRP levels was 1.27 (1.09–1.48) in the total
study samples, 1.53 (1.20–1.94) in those with HbA1c
≥6.5% at blood collection, and 1.06 (0.85–1.33) in those
with HbA1c <6.5% at blood collection (Table 2).
We further stratified the analysis by sex (Table 3) and
baseline BMI status (Table 4). The association was slightly
stronger in women compared to men, but the interaction
was not statistically significant (P for interaction = 0.27).
The association was similar in normal weight individuals
(BMI <23 kg/m2) and overweight/obese participants
(BMI ≥23 kg/m2), and the interaction test was not
significant (P for interaction = 0.72).
Discussion
In this prospective nested case–control study of Chinese
men and women, elevated baseline plasma CRP levels
were associated with an increased risk of T2D. However,
when stratified by baseline HbA1c levels, we found that
CRP was only positively associated with T2D among
those already with high HbA1c levels (undiagnosed dia-
betes), but not in those with low HbA1c levels (incident
diabetes). Therefore, elevated CRP levels might be by-
products of hyperglycemia, rather than directly contrib-
uting to the development of incident T2D.
HbA1c was adapted as a diagnosis criterion of diabetes
in 2010 by the American Diabetes Association [19];
therefore, at the time of blood collection and follow-up
in our cohort, HbA1c level was not used in the diagnosis
of diabetes in Singapore. In the total study samples, irre-
spective of HbA1c levels in the cases, we observed a
strong positive association between CRP and T2D. The
estimate (OR = 1.27 [95% CI 1.09–1.48] per 1 log mg/L
increment in CRP levels) was consistent with the pooled
relative risk reported from a recent meta-analysis [1.26
(95% CI 1.16–1.37); 18 studies] [2]. None of the previous
studies included HbA1c in their diagnosis criteria, and
two prior studies in Caucasian populations have ob-
served positive CRP-T2D associations among subgroup
subjects with HbA1c <5.8% [20] and HbA1c <6.0% [21],
respectively, which were contrary to the findings of the
current study. Both studies have also adjusted for HbA1c
in the statistical models, and the positive association be-
tween CRP and incident diabetes did not change materi-
ally [20, 21]. We did not adjust for HbA1c levels in our
model, because we had purposely excluded controls with
baseline HbA1c ≥6.0% to reduce the possibility of un-
diagnosed diabetes among the controls. Therefore, the
cases had much higher HbA1c levels compared with the
controls at the time of blood collection (Table 1), and
adjustment for the Hb1Ac levels would be problematic
due to its marked difference between cases and controls.
Since no other studies have specifically evaluated the ef-
fect of high HbA1c levels at baseline among the incident
diabetes cases, it is unclear to what extent the positive
association in previous prospective reports could be ex-
plained by the effect of undiagnosed diabetes. Some
studies also found no significant associations between
CRP and incident diabetes in Pima Indians [22], UK
adults [18], Aboriginal Canadians [23], Germany men
[24], Mexican men [25], and US adults [26]. Several
studies have suggested that CRP-diabetes association
could be largely explained by obesity [23, 24, 26, 27],
Table 1 Characteristics of the diabetes cases and matched
controls: The Singapore Chinese Health Study
Characteristics Cases Controls p value*
Number of participants 571 571 -
Age, years 59.6 ± 6.1 59.7 ± 6.2 0.78
Gender (Male) 236 (41.3) 236 (41.3) -
Dialect (%) -
Cantonese 287 (50.3) 287 (50.3)
Hokkien 284 (49.7) 284 (49.7)
Body mass index, kg/m2 24.8 ± 3.6 22.8 ± 3.3 <0.001
Level of education (%) 0.15
No formal education 104 (18.2) 99 (17.3)
Primary school 255 (44.7) 233 (40.8)
Secondary school or higher 212 (37.1) 239 (41.9)
Cigarette smoking (%) 0.08
Never smokers 410 (71.8) 425 (74.4)
Ever smokers 161 (28.2) 146 (25.6)




< 0.5 hours/week 456 (79.9) 454 (79.5)
0.5–3.9 hours/week 82 (14.4) 68 (11.9)
≥ 4 hours/week 33 (5.8) 49 (8.6)
Alcohol intake (%) 0.81
Abstainers 498 (87.2) 497 (87.0)
Weekly drinkers 55 (9.6) 59 (10.3)
Daily drinkers 18 (3.2) 15 (2.6)
C-reactive protein, mg/L 2.79 ± 2.65 1.86 ± 2.03 <0.001
HbA1c, % 6.83 ± 1.44 5.55 ± 0.27 <0.001
Random glucose, mmol/L 7.27 ± 3.65 4.84 ± 1.22 <0.001
Random insulin, mIU/L 27.8 ± 33.8 18.0 ± 22.5 <0.001
Total cholesterol, mmol/L 5.31 ± 0.95 5.20 ± 0.85 0.049
HDL cholesterol, mmol/L 1.08 ± 0.24 1.23 ± 0.32 <0.001
Triglyceride, mmol/L 2.44 ± 1.53 1.80 ± 1.04 <0.001
Data are expressed as mean ± standard deviation for continuous variables and
n (percentage) for categorical variables
Cases and controls are matched on age at blood taken (±3 years), gender,
dialect, and date of blood collection (±6 months)
*p values based on the chi-square test for categorical variables and Student’s t-
test for continuous variables
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insulin resistance [26, 27], deranged liver function and
lower adiponectin levels [18].
The stronger association between CRP and glycemia
in Chinese women compared to men in some studies
[7, 8, 11, 28] may be explained by the greater accu-
mulation of subcutaneous fat in women than in men
[29]. Two prospective cohort studies in Mexican [25]
and German [30] populations observed positive CRP-
T2D associations in women but not in men, while two co-
hort studies in Japanese populations [3, 4] found no sig-
nificant gender differences in the association. In our study,
although no significant interaction was observed between
sex and CRP (P = 0.27), the association with T2D risk was
stronger in women compared to men when CRP was ex-
amined as a continuous variable, and this finding is gener-
ally consistent with previous prospective studies [18].
Our finding of a positive association between CRP and
increased risk of undiagnosed diabetes but not incident
diabetes suggests that CRP might not be a causal factor
for diabetes, but is a marker of hyerglycaemia in the
pathway. Although the meta-analysis revealed a statisti-
cally significant increased diabetes risk associated with
CRP [2], the results are not entirely consistent and a
number of studies did not report any significant associ-
ation either in the whole population [18, 22, 23, 26] or
in men [24, 25]. The current evidence remains contro-
versial whether CRP is a causal risk factor or just a
downstream intermediate for T2D [31]. Hence, the clinical
potential of targeting CRP in the prevention of diabetes
remains uncertain. A recent Mendelian randomization
analysis in the Whitehall II Study found that CRP haplo-
types were not associated with incident diabetes despite
the association with baseline serum CRP [32]. Other
Mendelian randomization studies also found no causal
relation between CRP and metabolic syndrome [33],
as well as coronary heart disease [34–36]. Therefore,
the lack of concordance between the effect of CRP
genotypes and CRP levels on T2D and coronary heart
disease risks argues against a causal role of CRP in
the etiologies of these two diseases.
The strength of the present study was its prospective de-
sign and hence the presumed lack of recall bias in expos-
ure data (questionnaires, collected biospecimens) prior to
T2D diagnosis. However, there are some limitations to the
Table 2 Risk of diabetes according to quartiles of hs-CRP: The Singapore Chinese Health Study
Quartiles of hs-CRPa P for trendb Per 1 log mg/L
increaseQ1 Q2 Q3 Q4
Median (range) 0.4 (0.1–0.6) 0.9 (0.7–1.2) 1.6 (1.3–2.3) 3.6 (2.4–11.0)
Total diabetes
Cases/controls 78/154 107/139 150/138 236/140
Model 1 1.00 1.51 (1.03–2.20) 2.14 (1.47–3.11) 3.25 (2.28–4.64) <0.001 1.59 (1.40–1.81)
Model 2 1.00 1.42 (0.96–2.11) 1.89 (1.27–2.80) 2.70 (1.85–3.95) <0.001 1.50 (1.31–1.71)
Model 3 1.00 1.23 (0.81–1.86) 1.50 (0.99–2.27) 1.97 (1.32–2.94) <0.001 1.34 (1.16–1.54)
Model 4 1.00 1.24 (0.79–1.96) 1.22 (0.77–1.92) 1.74 (1.12–2.70) 0.016 1.27 (1.09–1.48)
Undiagnosed diabetes
Cases/controls 32/81 43/67 73/54 131/77
Model 1 1.00 1.48 (0.84–2.62) 3.63 (2.02–6.53) 4.39 (2.59–7.45) <0.001 1.84 (1.52–2.24)
Model 2 1.00 1.29 (0.71–2.37) 3.17 (1.72–5.82) 3.63 (2.08–6.36) <0.001 1.75 (1.43–2.14)
Model 3 1.00 1.21 (0.64–2.28) 2.41 (1.26–4.59) 2.55 (1.42–4.58) <0.001 1.53 (1.24–1.89)
Model 4 1.00 1.20 (0.59–2.44) 2.17 (1.07–4.40) 2.43 (1.25–4.71) 0.003 1.53 (1.20–1.94)
Incident diabetes
Cases/controls 46/73 64/72 77/84 105/63
Model 1 1.00 1.45 (0.87–2.43) 1.45 (0.88–2.39) 2.54 (1.54–4.20) <0.001 1.38 (1.16–1.64)
Model 2 1.00 1.50 (0.85–2.65) 1.24 (0.70–2.18) 2.20 (1.26–3.84) 0.008 1.31 (1.08–1.59)
Model 3 1.00 1.31 (0.73–2.36) 1.07 (0.60–1.93) 1.70 (0.95–3.07) 0.14 1.20 (0.98–1.47)
Model 4 1.00 1.24 (0.65–2.39) 0.75 (0.39–1.45) 1.24 (0.64–2.39) 0.93 1.06 (0.85–1.33)
Abbreviation: hs-CRP high-sensitive C-reactive protein, OR odds ratio, CI confidence interval
aQuartiles of hs-CRP were created based on controls in the whole population
bLinear trend was tested by using the median level of each quartile of hs-CRP as continuous variables
Model 1: adjusted for age (continuous variable), matched on age (±3 years), sex, dialect, and date of blood collection (±6 months)
Model 2: model 1 plus education level, smoking status, alcohol intake, physical activity, hypertension, and fasting status
Model 3: model 2 plus adjusted for body mass index (continuous)
Model 4: model 3 plus plasma triglycerides and HDL-cholesterol levels (both in quartiles)
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present study as well. First, we measured CRP only once
at baseline and this may not represent the long-term lipid
profile. However, this would lead to non-differential mis-
classification and may underestimate the association. In
addition, the BMI was calculated from self-reported height
and weight, and residual confounding is possible. Second,
incident diabetes was obtained from self-reported infor-
mation, thus undiagnosed diabetes may exist. However,
we have measured HbA1c levels, which was updated as a
diagnosis criterion of diabetes in 2010 by the American
Diabetes Association [19], and further performed stratified
analysis among subgroups with HbA1c <6.5% and ≥6.5%.
Table 4 Risk of diabetes according to quartiles of hs-CRP: stratified by baseline BMI
Quartiles of hs-CRPa P for trendb Per 1 log mg/L
increaseQ1 Q2 Q3 Q4
Median (range) 0.4 (0.1–0.6) 0.9 (0.7–1.2) 1.6 (1.3–2.3) 3.6 (2.4–11.0)
BMI <23 kg/m2
Cases/controls 37/109 42/84 48/68 59/57
Model 1 1.00 1.49 (0.88–2.53) 2.08 (1.23–3.51) 2.95 (1.75–4.99) <0.001 1.47 (1.22–1.77)
Model 2 1.00 1.41 (0.82–2.43) 1.93 (1.12–3.32) 2.67 (1.54–4.60) <0.001 1.42 (1.17–1.72)
Model 3 1.00 1.27 (0.71–2.25) 1.38 (0.77–2.47) 2.07 (1.16–3.70) 0.02 1.29 (1.05–1.58)
BMI ≥23 kg/m2
Cases/controls 41/45 65/55 102/70 177/83
Model 1 1.00 1.39 (0.79–2.44) 1.74 (1.02–2.96) 2.62 (1.56–4.41) <0.001 1.55 (1.29–1.86)
Model 2 1.00 1.30 (0.73–2.33) 1.43 (0.82–2.50) 2.19 (1.28–3.78) 0.002 1.46 (1.21–1.77)
Model 3 1.00 1.11 (0.60–2.05) 1.20 (0.67–2.15) 1.68 (0.95–2.97) 0.041 1.33 (1.09–1.63)
Abbreviation: hs-CRP high-sensitive C-reactive protein, BMI body mass index, OR odds ratio, CI confidence interval
aQuartiles of hs-CRP were created based on controls in the whole population
bLinear trend was tested by using the median level of each quartile of hs-CRP as continuous variables
Model 1: adjusted for age (continuous variable), sex, and dialect
Model 2: model 1 plus education level, smoking status, alcohol intake, physical activity, hypertension, and fasting status
Model 3: model 2 plus plasma triglycerides and HDL-cholesterol levels (both in quartiles)
Table 3 Risk of diabetes according to sex-specific quartiles of hs-CRP: stratified by sex
Quartiles of hs-CRPa P for trendb Per 1 log mg/L
increaseQ1 Q2 Q3 Q4
Men
Median (range) 0.3 (0.12–0.4) 0.8 (0.5–1.1) 1.5 (1.2–2.0) 3.4 (2.1–11.0)
Cases/controls 22/60 70/64 59/53 85/59
Model 1 1.00 2.79 (1.54–5.05) 3.00 (1.60–5.63) 3.73 (2.04–6.79) 0.002 1.46 (1.21–1.75)
Model 2 1.00 3.42 (1.77–6.61) 3.06 (1.53–6.13) 3.57 (1.80–7.11) 0.039 1.38 (1.12–1.70)
Model 3 1.00 2.76 (1.40–5.47) 2.45 (1.20–5.03) 2.80 (1.38–5.69) 0.029 1.30 (1.05–1.61)
Model 4 1.00 2.86 (1.36–6.01) 1.90 (0.86–4.19) 2.25 (1.06–4.79) 0.24 1.19 (0.94–1.49)
Women
Median (range) 0.5 (0.12–0.7) 1.1 (0.8–1.3) 1.8 (1.4–2.5) 4.3 (2.6–11.0)
Cases/controls 44/94 56/79 87/82 148/80
Model 1 1.00 1.53 (0.91–2.57) 2.29 (1.38–3.80) 3.86 (2.39–6.21) <0.001 1.72 (1.44–2.04)
Model 2 1.00 1.37 (0.79–2.37) 2.00 (1.16–3.46) 3.32 (1.99–5.53) <0.001 1.63 (1.36–1.96)
Model 3 1.00 1.10 (0.61–2.00) 1.45 (0.80–2.66) 2.19 (1.24–3.85) 0.002 1.42 (1.16–1.73)
Model 4 1.00 1.09 (0.54–2.20) 1.25 (0.63–2.47) 2.07 (1.07–3.99) 0.012 1.41 (1.12–1.78)
Abbreviation: hs-CRP high-sensitive C-reactive protein, OR odds ratio, CI confidence interval
aQuartiles of hs-CRP were created separately for men and women among controls
bLinear trend was tested by using the median level of each quartile of hs-CRP as continuous variables
Model 1: adjusted for age (continuous variable), matched on age (±3 years), sex, dialect, and date of blood collection (±6 months)
Model 2: model 1 plus education level, smoking status, alcohol intake, physical activity, hypertension, and fasting status
Model 3: model 2 plus adjusted for body mass index (continuous)
Model 4: model 3 plus plasma triglycerides and HDL-cholesterol levels (both in quartiles)
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Furthermore, we have used HbA1c as a selection criterion
for controls to minimize bias due to undiagnosed diabetes;
therefore, we could not include it in our model adjust-
ment. Last but not least, the present study was conducted
in a middle-aged and elderly population with a higher
diabetes incidence, therefore, the findings may not be
generalizable to younger people.
Conclusion
In conclusion, we found that elevated plasma levels of hs-
CRP were only positively associated with T2D among
those already with high HbA1c levels, but not in those
with low HbA1c levels in this Chinese population. There-
fore, elevated CRP levels may be a consequence of hyper-
glycemia, instead of being an etiological biomarker in
T2D development. Current evidence remains controver-
sial whether CRP is a causal risk factor or just a down-
stream intermediate for T2D. Therefore, more carefully
constructed prospective studies in different populations
are warranted to validate this finding, and investigate the
biochemical and genetic basis for the relationship between
hs-CRP and T2D risk.
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